Skip to main content
SpringerLink
Log in

Kopf- und Halstumoren

  • Chapter
Book cover Therapiekonzepte Onkologie

Zusammenfassung

Kopf-Hals-Tumoren beschreiben als Überbegriff eine Vielzahl verschiedener Tumoren im ORL-Bereich. Trotz unterschiedlicher Lokalisation sind die Grundprinzipien der Behandlung gleich [1–4], so daß hier auf eine ausführliche separate Beschreibung jeder einzelnen Tumorlokalisation verzichtet wird.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Medical progress: Head and neck cancer. N Engl J Med 328:184–194

    Article  PubMed  CAS  Google Scholar 

  2. Stupp R, Vokes EE (1995) Progress in treatment of head and neck cancer. Part 1: Chemotherapy. Strahlenther Onkol 171:12–17

    PubMed  CAS  Google Scholar 

  3. Stupp R, Vokes EE (1995) Progress in treatment of head and neck cancer. Part 2: chemoradiotherapy. Strahlenther Onkol 171:140–148

    PubMed  CAS  Google Scholar 

  4. Vokes E, Athanasiadis I (1996) Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7:15–29

    Article  PubMed  CAS  Google Scholar 

  5. Parker S, Tong T, Bolden S, Wingo P (1997) Cancer statistics, 1997. CA, Cancer J Clin 47:5–27

    Article  CAS  Google Scholar 

  6. Black R, Bray F, Ferlay J, Parkin D (1997) Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075–1107

    Article  PubMed  CAS  Google Scholar 

  7. Weickhardt U (1989) Ionisierende Strahlen Luzern: SUVA, Schweiz. Unfallversicherungsanstalt, 1989. Reihe Arbeitsmedizin; Merkblatt 4

    Google Scholar 

  8. Vader J, Minder C (1987) Die Sterblichkeit an Krebsen der Nasen- und Nasennebenhöhlen bei Schweizer Schreinern. Schweiz Med Wschr 117:481–486

    PubMed  CAS  Google Scholar 

  9. Maier H, Dietz A, Gewelke U, Heller WD (1992) Berufliche Exposition gegenüber Schadstoffen und Krebsrisiko im Bereich von Mundhöhle, Oropharynx, Hypopharynx und Larynx. Eine Fall-Kontrollstudie. Laryngo Rhino Otol 70: 93–98

    Article  Google Scholar 

  10. Acheson E, Cowdell R, Jolies B (1970) Nasal cancer in the Northhamptonshire bood and shoe industry. Br Med J 1:385–393

    Article  PubMed  CAS  Google Scholar 

  11. Fandi A, Altun M, Azli N, Armand JP, Cvitkiovic E (1994) Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21:382–397

    PubMed  CAS  Google Scholar 

  12. Cvitkovic E (1994) for the International Nasopharynx Study Group. Neoadjuvant chemotherapy with epirubicin, cisplatin, bleomycin in undifferentiated nasopharyngeal cancer: Preliminary results of an international phase III trial. Proc Am Soc Clin Oncol 13:283 (abstract # 915)

    Google Scholar 

  13. Al-Sarraf M, LeBlanc M, Giri PG, Fu K, Cooper J, Vuong T, Forastiere A, Adams G, Sakr W, Schuller D, Ensley J (1996) Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc Am Soc Clin Oncol 15:313 (abstract #882)

    Google Scholar 

  14. Spitz MR (1994) Epidemiology and risk factors for head and neck cancer. Semin Oncol 21:281–288

    PubMed  CAS  Google Scholar 

  15. Tuyns A, Esteve J, Raymond L, Berrino F, Benhamou E, Blanchet F, Boffetta P, Crosignani P, Del-Moral AL, W, Merletti F, Pequignot G, Riboli E, Sancho-Garnier H, Terracini B, Zubiri A, Zubiri L (1988) Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 41:483–491

    Article  PubMed  CAS  Google Scholar 

  16. Decker J, Goldstein J (1982) Risk factors in head and neck cancer. N Engl J Med 306:1151–1155

    Article  PubMed  CAS  Google Scholar 

  17. Ning JP, Yu MC, Wang QS, Henderson BE (1990) Consumption of salted fish and other risk factors for nasopharyngeal carcinoma (NPC) in Tianjin, a low-risk region for NPC in the People’s Republic of China. J Natl Cancer Inst 82:291–296

    Article  PubMed  CAS  Google Scholar 

  18. Liebovitz D (1994) Nasopharyngeal carcinoma: The Epstein-Barr virus association. Semin Oncol 21:376–381

    Google Scholar 

  19. TNM Classification of malignant tumours. (1997, 5th ed.). UICC International Union Against Cancer. Sobin LH, Wittekind Ch (eds) New York: Wiley-Liss, Inc.

    Google Scholar 

  20. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J (1994) Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 168:494–498

    Article  PubMed  CAS  Google Scholar 

  21. Alvi A, Johnson JT(1996) Extracapsular spread in the clinically negative neck (NO): Implications and outcome. Otolaryngol Head Neck Surg 114:65–70

    Article  PubMed  CAS  Google Scholar 

  22. Zbären P, Becker M, Lang H (1996) Pretherapeutic staging of laryngeal carcinoma: Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathology. Cancer 77:1263–1273

    Article  PubMed  Google Scholar 

  23. Merino O, Lindberg R, Fletcher G (1977) An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 40:145–151

    Article  PubMed  CAS  Google Scholar 

  24. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB (1993) Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71:452–456

    Article  PubMed  CAS  Google Scholar 

  25. Ellis ER, Mendenhall WM, Rao PV, Parsons JT, Spangler AE, Million RR (1998) Does node location affect the incidence of distant metastases in head and neck squamous cell carcinoma? Int J Radiat Oncol Biol Phys 17:293–297

    Article  Google Scholar 

  26. Zbären P, Lehmann W (1987) Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113:762–764

    Article  PubMed  Google Scholar 

  27. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP (1987) Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154:439–442

    Article  PubMed  CAS  Google Scholar 

  28. Sloan D, Goepfert H (1991) Conventional therapy of head and neck cancer. Hematol Oncol Clin North Am 5:601–625

    PubMed  CAS  Google Scholar 

  29. Scher N, Panje WR (1991) New concepts in head and neck surgery. Hematol Oncol Clin North Am 5:627–634

    PubMed  CAS  Google Scholar 

  30. Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW (1991) Standardizing neck dissection terminology. Official report of the Academy’s Committee for Head and Neck Surgery and Oncology. Arch Otolaryngol Head Neck Surg 117:601–605

    Article  PubMed  CAS  Google Scholar 

  31. Spiro RH, Strong EW, Shah JP (1994) Classification of neck dissection: Variations on a new theme. Am J Surg 168:415–418

    Article  PubMed  CAS  Google Scholar 

  32. Dubben HH, Baumann M, Fassbender T, Beck-Bornholdt HP (1992) Hyperfractionated radiotherapy of head and neck tumours. Strahlenther Onkol 168:373–382

    PubMed  CAS  Google Scholar 

  33. Dadian G, Riches PG, Henderson DC, MacLennan K, Lorentzos A, Moore J, Hobbs JR, Gore ME (1993) Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 29b:29–34

    Article  PubMed  CAS  Google Scholar 

  34. Dische S (1994) Radiotherapy — new fractionation schemes. Semin Oncol 21: 304–310

    PubMed  CAS  Google Scholar 

  35. Peters LJ, Ang KK, Thames HD Jr (1988) Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol 27:185–194

    Article  PubMed  CAS  Google Scholar 

  36. Horiot JC, Le Fur R, N’Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M, Van Glabbeke M, De Pauw M (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241

    Article  PubMed  CAS  Google Scholar 

  37. Ma J, Verweij J, Planting AS, de Boer Dennert M, van der Burg ME, Stoter G, Schellens JH (1994) Pharmacokinetic-dynamic relationship of weekly high-dose cisplatin (C) in solid tumor patients (pts). Proc Am Soc Clin Oncol 13:133 (abstract # 325)

    Google Scholar 

  38. Marcial VA, Pajak TF, Chu C et al. (1987) Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: Preliminary report by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 13:41–47

    Article  PubMed  CAS  Google Scholar 

  39. Dische S, Saunders M (1990) The rationale for continuous, hyperfractionated and accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 13:41–47

    Google Scholar 

  40. Saunders MI, Dische S, Grosch EJ, Fermont DC, Ashford RFU, Maher EJ, Makepeace AR (1991) Experience with CHART. Int J Radiat Oncol Biol Phys 21:871–878

    Article  PubMed  CAS  Google Scholar 

  41. Saunders MI, Dische S, Barrett A, Parmar MKB, Harvey A, Gibson D, on behalf of the CHART steering committee, Aitken RG, Bomford CK, Coyle D, Cottier B, Davies M, Dawes P, Drummond MF, Gaffney C, Galpine A, Henk JM, Herrman T, Hince T, Littbrand B, et al. (1996) Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Br J Cancer 73:1455–1462

    Google Scholar 

  42. Horiot JC, Bontemps P, Begg AC, Le Fur R, Van Den Bogaert W, Bolla M, N’Guyen T, Van Den Weijngaert D, Bernier J, Lusinchi A, Stuschke D, Lopez Torrecilla D, Jancar B, Collette L, Van Glabbeke M, Pierart M (1996) Hyperfractionated and accelerated radiotherapy in head and neck cancer: Results of the EORTC trials and impact on clinical practice. Bull Cancer Radiother 83:314–320

    Article  PubMed  CAS  Google Scholar 

  43. Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L (1990) Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347–1350

    Article  PubMed  CAS  Google Scholar 

  44. Wendt TG, Hartenstein RC, Wustrow TP, Lissner J (1989) Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: A phase II study. J Clin Oncol 7:471–476

    PubMed  CAS  Google Scholar 

  45. Glanzmann C, Lütolf UM (1992) Follow-up data of our pilot study on concomitant hyper-fractionated radiotherapy and cisplatinum (CDDP) in patients with advanced cancer of the head and neck. Strahlenther Onkol 168:453–456

    PubMed  CAS  Google Scholar 

  46. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR (1994) Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 12:2351–2359

    PubMed  CAS  Google Scholar 

  47. Kies MS, Haraf DJ, Mittal B, Stenson K, Athanasiadis I, Kozloff M, Miller M, Pelzer H, Wenig B, Weichselbaum R, Vokes EE (1996) Intensive combined therapy with C-DDP, 5-FU, hydroxyurea, and bid radiation (C-FHX) for stage IV squamous cancer (SCC) of the head and neck. Proc Am Soc Clin Oncol 15:314 (abstract # 886)

    Google Scholar 

  48. Munro AJ (1995) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83–91

    Article  PubMed  CAS  Google Scholar 

  49. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838–847

    PubMed  CAS  Google Scholar 

  50. a. Bourhis J, Pignon J, Designé L, Luboinski B, Guérin S, Domenge C (1998) On behalf of the MACH-NC Collaborative Group. Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): Locoregional treatment vs same treatment + chemotherapy. Proc Am Soc Clin Oncol; 17: (abstract) in press

    Google Scholar 

  51. O’Brien M, Schofield JB, Lorentzos A, Moore J, Atkinson H, Henk JM, Mac Lennan KA, Gore ME (1994) The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 30b:265–267

    Article  PubMed  Google Scholar 

  52. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, De Mulder PHM, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526

    PubMed  CAS  Google Scholar 

  53. Al-Sarraf M (1988) Head and Neck Cancer: Chemotherapy Concepts. Semin Oncol 15:70–85

    PubMed  CAS  Google Scholar 

  54. Liverpool Head and Neck Oncology Group (1990) A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311–315

    Article  Google Scholar 

  55. Jacobs C, Lyman G, Velez Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263

    PubMed  CAS  Google Scholar 

  56. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D (1986) Carboplatin (NSC-241–240): An active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4:1506–1509

    PubMed  CAS  Google Scholar 

  57. Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart J, Schuller D, Coltman CJ (1987) Platinum analogs in recurrent and advanced head and neck cancer: A Southwest Oncology Group and Wayne State University study. Cancer Treat Rep 71: 723–726

    PubMed  CAS  Google Scholar 

  58. Adenis L, Hossfeld D, Schmoll HJ, Arnold H, Martin A, Canetta R (1990) Phase II study of carboplatin in head and neck cancer (Meeting abstract). Ann Oncol 1:66

    Google Scholar 

  59. Hong WK, Bromer R (1983) Chemotherapy in head and neck cancer. N Engl J Med 308:75–79

    Article  PubMed  CAS  Google Scholar 

  60. Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS, Waun Ki H (1996) A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol Cancer Clin Trials. 19:379–383

    CAS  Google Scholar 

  61. Martin M, Diaz Rubio E, Gonzalez Larriba JL, Casado A, Sastre J, Lopez Vega JM, Almenarez J, Dominguez S (1993) Ifosfamide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 31:340–342

    Article  PubMed  CAS  Google Scholar 

  62. Pai VR, Parikh DM, Mazumdar AT, Rao RS (1993) Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology 50:86–91

    Article  PubMed  CAS  Google Scholar 

  63. Buesa JM, Fernandez R, Esteban E, Estrada E, Baron FJ, Palacio I, Gracia M, Lacave AJ (191) Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 2:151–152

    Google Scholar 

  64. Cervellino JC, Araujo CE, Pirisi C, Francia A, Cerruti R (1991) Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A Getlac Study. Oncology 48:89–92

    Article  PubMed  CAS  Google Scholar 

  65. Kish JA, Tapazoglou E, Ensley J, Al Sarraf M (1990) Activity of ifosfamide (NSC-109724) in recurrent head and neck cancer patients (Meeting abstract). Proc Am Assoc Cancer Res 31: A1130

    Google Scholar 

  66. Canfield V, Saxman S, Kolodziej M, Harrison-Mann B, Loehrer P, Vokes E (1997) Phase II trial of vinorelbine in advanced or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 16:387a (abstract # 1382)

    Google Scholar 

  67. Oliveira J, Geofîrois L, Rolland F, Degardin M, Armand J, Boudillet J, P Tresca P, Lentz M, Vanglabbeke M, Fumoleau P (1997) Activity of Navelbinee on lesions within previously irradiated fields in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck: an EORTC-ECSG study. Proc Am Soc Clin Oncol 16:406a (abstract # 1449)

    Google Scholar 

  68. Testolin A, Recher G, Pozza F, Panizzoni GA, Gasparini G (1994) Vinorelbine in pretreated advanced head and neck squamous cell carcinoma: a phase II study. Proc Am Soc Clin Oncol 13:289 (abstract # 938)

    Google Scholar 

  69. Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Ingria F, Cannata G, Gebbia N (1993) A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29 a: 1358–1359

    Article  Google Scholar 

  70. Stewart DJ, Cripps MC, Lamothe A, Laframboise G, Odell P, Gerin Lajoie J (1993) Doxorubicin plus metronidazole in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 16:113–116

    Article  PubMed  CAS  Google Scholar 

  71. Smith RE, Thornton DE, Allen J (1995) A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22:41–46

    PubMed  CAS  Google Scholar 

  72. Forastiere AA, Neuberg D, Taylor SG, DeConti R, Adams G (1993) Phase II evaluation of Taxol in advanced head and neck cancer:an Eastern Cooperative Oncology Group Trial (Meeting abstract). Proc Am Soc Clin Oncol 12:277 (abstract # 893)

    Google Scholar 

  73. Thornton D, Singh K, Putz B, Gams R, Schuller D, Smith R (1994) A Phase II trial of Taxol in squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 13:288 (abstract # 933)

    Google Scholar 

  74. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, Groult V, Janot F, de Forni M, Armand J (1998) A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. in press

    Google Scholar 

  75. Ebihara S, Fujii H, Sasaki Y, Inuyama Y (1997) A late phase II study of docetaxel (Taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 16:399a (abstract # 1425)

    Google Scholar 

  76. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672–1678

    PubMed  CAS  Google Scholar 

  77. Catimel G, Verweis J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB (1994) Docetaxel (Taxotere ®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533–537

    PubMed  CAS  Google Scholar 

  78. Catimel G, Vermorken JB, Clavel M, De Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweis J, Wanders J, Franklin H, Kaye SB (1994) A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543–547

    PubMed  CAS  Google Scholar 

  79. Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley IF (1996) Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs 14:403–407

    PubMed  CAS  Google Scholar 

  80. Robert F, Wheeler RH, Molthrop DC, Greene P, Chen S (1994) Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent. Proc Am Soc Clin Oncol 13:281 (abstract # 905)

    Google Scholar 

  81. De Andres L, Brunet J, Lopez-Pousa A, Burgues J, Vega M, Tabernero JM, Mescia R, Lopez JJ (1995) Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13:1493–1500

    PubMed  Google Scholar 

  82. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245–1251

    PubMed  CAS  Google Scholar 

  83. Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Kozloff M, Mittal B, Pelzer H, Wenig B, Panje W, Weichselbaum RR (1995) Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 13:876–883

    PubMed  CAS  Google Scholar 

  84. Vokes EE, Mick R, Lester EP, Panje WR, Weichselbaum RR (1991) Cisplatin and Fluorouracil Chemotherapy Does Not Yield Long-Term Benefit In Locally Advanced Head and Neck Cancer: Results From a Single Institution. J Clin Oncol 9:1376–1384

    PubMed  CAS  Google Scholar 

  85. Vokes EE, Weichselbaum RR, Mick R, McEvilly JM, Haraf DJ, Panje WR (1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:877–882

    Article  PubMed  CAS  Google Scholar 

  86. Stupp R, Haraf D, Kozloff M, McEvilly J, Weichselbaum RR (1993) Long term experience with cisplatin-based induction chemotherapy in locally advanced head and neck cancer. Eur J Cancer 29A(Suppl 6):S146

    Article  Google Scholar 

  87. Clark J, Busse P, Norris C, Jr, Dreyfuss A, Rossi R, Poulin M, Thornhill L, Costello R, Lackey M, Posner M (1996) Long term results of induction chemotherapy with cisplatin, 5-FU and high dose leucovorin (PFL) for squamous cell carcinoma of the head and neck (SCCHN) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 15:317 (abstract # 897)

    Google Scholar 

  88. Dreyfuss A, Clark JR, Wright JE, Norris CM Jr, Busse PM, Lucarini JW, Fallon BG, Casey D, Andersen JW, Klein R, Rosowsky A, Miller D, Frei E, III (1990) Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167–172

    Article  PubMed  CAS  Google Scholar 

  89. Tennvall J, Albertsson M, Biorklund A, Wennerberg J, Anderson H, Andersson T, Einer A, Mercke C (1991) Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck. Acta Oncol 30:27–32

    Article  PubMed  CAS  Google Scholar 

  90. Abele R, Honegger HP, Grossenbacher R et al. (1987) A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol 23:47–53

    Article  PubMed  CAS  Google Scholar 

  91. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M (1985) A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous carcinoma of the head and neck. Cancer 56:2740–2744

    Article  PubMed  CAS  Google Scholar 

  92. Forastiere AA (1991) Randomized trials of induction chemotherapy. A critical review. Hematol Oncol Clin North Am 5:725–736

    PubMed  CAS  Google Scholar 

  93. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690

    Article  Google Scholar 

  94. Stupp R, Weichselbaum RR, Vokes EE (1994) Combined modality therapy of head and neck cancer. Semin Oncol 21:349–358

    PubMed  CAS  Google Scholar 

  95. Forastiere A (1996) Another look at induction chemotherapy of organ preservation in patients with head and neck cancer (editorial). J Natl Cancer Inst 1996: 855–856

    Article  Google Scholar 

  96. Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, T S, for the EORTC Head and Neck Cooperative Group (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Reserach and Treatment of Cancer phase III trial. J Natl Cancer Inst 88:890–899

    Google Scholar 

  97. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, Endrizzi L, Bari M, Sampognaro E, Balli M, Gava A, Pappagallo GL, Fiorentino MV (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265–272

    Article  PubMed  CAS  Google Scholar 

  98. Wolf G, Hong W, Fisher S, Spaulding M, Endicott J, Laramore G, Hillman R, McClatchey K, Fye C (1993) Larynx preservation with induction chemotherapy (CT) and radiation (XRT) in advanced laryngeal cancer: final results of the VA Laryngeal Cancer Study Group Cooperative Trial. Proc Am Soc Clin Oncol 12:277 (abstract # 892)

    Google Scholar 

  99. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG, Campbell BH (1992) Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on intergroup study 0034. Int J Radiat Oncol Biol Phys 23:705–713

    Article  PubMed  CAS  Google Scholar 

  100. Schuller DE, Metch B, Mattox D, Stein D, McCracken JD (1988) Prospective chemotherapy in advanced head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98:1205–1211

    Article  PubMed  CAS  Google Scholar 

  101. Head and Neck Contracts Program (1987) Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report. Cancer 60:301–311

    Article  Google Scholar 

  102. Jacobs C, Makuch R (1990) Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8:838–847

    PubMed  CAS  Google Scholar 

  103. Stupp R, Vokes EE (1995) 5-FU plus radiation for head and neck cancer. J Infus Chemother 5:55–60

    PubMed  CAS  Google Scholar 

  104. Vokes EE, Weichselbaum RR (1990) Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 8:911–934

    PubMed  CAS  Google Scholar 

  105. Vokes E (1993) Interactions of chemotherapy and radiation. Semin Oncol 20:70–79

    PubMed  CAS  Google Scholar 

  106. Stupp R, Haraf D, Malone D, Moran W, Vokes EE (1994) Continous infusion paclitaxel, c.i. 5-Fluorouracil, oral hydroxyurea and concomitant radiotherapy with G-CSF-support for the treatment of head and neck cancer. Ann Oncol 5 (Suppl 8):114 (abstract # 573)

    Google Scholar 

  107. Brockstein B, Haraf D, Stenson K, Fasanmade A, Stupp R, Glisson B, Ratain M, Sulzen L, Klepsch A, RR W, Vokes E (1998) A phase I study of concomitant chemoradiotherapy with paclitaxel, 5-FU, and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis cancer of the head and neck. J Clin Oncol 16:735–744

    PubMed  CAS  Google Scholar 

  108. Fu KK, Cooper JS, Marcial VA, Laramore GE, Pajak TF, Jacobs J, Al Sarraf M, Forastiere AA, Cox JD (1996) Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 35:425–438

    Article  PubMed  CAS  Google Scholar 

  109. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648–2653

    PubMed  CAS  Google Scholar 

  110. Lo TC, Wiley Jr AL, Ansfield FJ, Brandenburg JH, Davis Jr HL, Gollin FF, Johnson RO, Ramiorez G, Vermund H (1976) Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcionoma of the oral cavity and oropharynx. A randomized study. Am J Roentgenol 126:229–235

    Article  CAS  Google Scholar 

  111. Bachaud JM, David JM, Boussin G, Daly N (1991) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 20:243–246

    Article  PubMed  CAS  Google Scholar 

  112. Glicksman AS, Slotman G, Doolittle C, III, Clark J, Koness J, Coachman N, Posner M, DeRosa E, Wanebo H (1994) Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 30:1043–1050

    Article  PubMed  CAS  Google Scholar 

  113. Glicksman AS, Wanebo H, Landmann C, Slotman G, Clark J, Doolittle C, Coachman N, Liu L, Koness J, DeRosa E, et al. (1995) Concurrent cisplatin based chemotherapy and accelerated hyperfractionated radiotherapy with late intensification in advanced head and neck cancer. Proc Am Soc Clin Oncol 14:295 (abstract # 846)

    Google Scholar 

  114. Wibault P, Bensmaine MEA, De Forni M, Armand JP, Bernai ET, Guillot T, Recondo G, Domenge C, Janot F, Borel C, Luboinski B, Eschwege F, Cvitkovic E (1996) Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: A phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J Clin Oncol 14:1192–1200

    PubMed  CAS  Google Scholar 

  115. Brizel D, Albers M, Fisher S, Scher R, Richtsmeier W, Clough R, George S, Prosnitz L (1997) A phase III trial of hyperfractionated irradiation 1 concurrent chemotherapy for locally advanced carcinoma of the head and neck: superiority of combined modality treatment. Proc Am Soc Clin Oncol 16:384a (abstract # 1368)

    Google Scholar 

  116. Haffty BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli A, Fischer JJ (1997) Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol 15:268–276

    PubMed  CAS  Google Scholar 

  117. Gupta NK, Pointon RC, Wilkinson PM (1987) A Randomised Clinical Trial to Contrast Radiotherapy With Radiotherapy and Methotrexate Given Synchronously In Head and Neck Cancer. Clin Radiol 38:575–581

    Article  PubMed  CAS  Google Scholar 

  118. Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, Friedman MA, Kohler M, McWhirter K, Carter SK (1987) Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California oncology group randomized trial. J Clin Oncol 5:1410–1418

    PubMed  CAS  Google Scholar 

  119. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Kozloff M, Stupp R, Wenig B, Moran W, Panje W, Weichselbaum RR (1994) Concomitant chemoradiotherapy for intermediate stage head and neck cancer. Proc Am Soc Clin Oncol 13:282 (abstract # 909)

    Google Scholar 

  120. Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR (1991) Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol 14:419–426

    Article  PubMed  CAS  Google Scholar 

  121. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR (1989) Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: A phase I-II study. J Clin Oncol 7:761–768

    PubMed  CAS  Google Scholar 

  122. Adelstein DJ, Sharan VM, Earle AS, Shah AC, Vlastou C, Haria CD, Damm C, Carter SG, Hines JD (1990) Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer 65:1685–1691

    Article  PubMed  CAS  Google Scholar 

  123. Keane T, Cummings B, O’Sullivan B, Payne D, Rawlinson E, MacKenzie R, Danjoux C, Hodson I (1993) A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 25:613–618

    Article  PubMed  CAS  Google Scholar 

  124. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F, Margarino G, Brema F, Pastorino G, Marziano C, Grimaldi A, Scasso F, Sperati G, Pallestrini E, Garaventa G, Accomando E et al. (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327:1115–1121

    Article  PubMed  CAS  Google Scholar 

  125. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88:583–589

    Article  PubMed  CAS  Google Scholar 

  126. Leyvraz S, Pasche P, Bauer J, Bernasconi S, Monnier P (1994) Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: Four-year results of a phase I/II study. J Clin Oncol 12:1876–1885

    PubMed  CAS  Google Scholar 

  127. Hamasaki VK, Vokes EE (1995) Interferons and other cytokines in head and neck cancer. Med Oncol 12:23–33

    Article  PubMed  CAS  Google Scholar 

  128. Dimery IW, Jacobs C, Tseng AJ, Saks S, Pearson G, Hong WK, Gutterman JU (1989) Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma. J Biol Response Mod 8:221–226

    PubMed  CAS  Google Scholar 

  129. Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH (1990) Phase I–II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 116:1271–1277

    Article  PubMed  CAS  Google Scholar 

  130. Schantz SP, Clayman GL, Dimery IW, Morice RL (1991) Combination interleukin-2 and interferon-alpha in head and neck cancer patients. Cancer Bull 42:133–145

    Google Scholar 

  131. Roth AD, Abele R, Alberto P (1994) 13-cis-Retinoic acid plus interferon-alpha: A phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 51:84–86

    Article  PubMed  CAS  Google Scholar 

  132. Cascinu S, Del Ferro E, Ligi M, Graziano F, Castellani, Catalano G (1996) Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy. Ann Oncol 7:538–539

    Article  PubMed  CAS  Google Scholar 

  133. Nikolaou AC, Fountzilas G, Daniilidis I (1996) Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study. J Laryngol Otol 110:857–861

    PubMed  CAS  Google Scholar 

  134. Wadler S, Schartz SL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignacies: a review. Cancer Res 50:3473–3486

    PubMed  CAS  Google Scholar 

  135. Benasso M, Merlano M, Blengio F, Cavallari M, Rosso R, Toma S (1993) Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 16:465–468

    Article  PubMed  CAS  Google Scholar 

  136. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G (1994) Cisplatin, 5-fluorouracil and interferon alpha 2 b for recurrent or metastatic head and neck cancer. Br J Cancer 69:392–393

    Article  PubMed  CAS  Google Scholar 

  137. Arquette MA, Mortimer JE, Loehrer PJ, Mandanas RA (1994) A phase II Hoosier oncology group trial of interferon alpha-2b(IFN) added to cisplatin (CDDP) and 5-fluorouracil (FU) in recurrent or metastatic head and neck cancer. Proc Am Soc Clin Oncol 13:280 (abstract # 901)

    Google Scholar 

  138. Vlock D, Leong T, Wonson W, Dutcher J, Adams G (1995) Phase II trial of interferon alpha (IFN) and chemotherapy in locally recurrent or metastatic head and neck cancer (SCCHN). Results of ECOG Trial Est 1390. Proc Am Soc Clin Oncol 14:303 (abstract # 881)

    Google Scholar 

  139. Hussain M, Benedetti J, Smith RE, Rodriguez GI, Schuller D, Ensley J (1995) Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. Cancer 76:1233–1237

    Article  PubMed  CAS  Google Scholar 

  140. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, Berezin F (1993) Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 11:360–368

    PubMed  CAS  Google Scholar 

  141. Valavaara R, Kortekangas AE, Nordman E, Cantell K (1992) Interferon combined with irradiation in the treatment of operable head and neck carcinoma. A pilot study. Acta Oncol 31:429–431

    Article  PubMed  CAS  Google Scholar 

  142. Schrijvers D, Johnson J, Jacob H, Jiminez U, Gore M, Boutis L, Szpirglas H, Robbins K, Oliveira J, Lewenson R, Schüller J, Riviere A, Arvay C, Langecker P, Cvitkovic C, Vokes E (1996) Modulation of cisplatin/5FU chemotherapy by interferon alfa in patients with recurrent or metastatic head and neck cancer: A phase III trial of the Head and Neck Interferon Cooperative Study Group. Proc Am Soc Clin Oncol 15:312 (abstract # 879)

    Google Scholar 

  143. Lippman S, Hong W (1989) Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17:691–694

    Article  PubMed  CAS  Google Scholar 

  144. Slaughter DP, Southwick HW, Smejkal W (1953) „Field cancerisation“in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6:963–968

    Article  PubMed  CAS  Google Scholar 

  145. Licciardello JTW, Spitz MR, Hong WK (1989) Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus and lung. Int J Radiat Oncol Biol Phys 17:467–476

    Article  PubMed  CAS  Google Scholar 

  146. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD et al. (1989) Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449–456

    Article  PubMed  CAS  Google Scholar 

  147. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK (1997) Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 89:199–211

    Article  PubMed  CAS  Google Scholar 

  148. Huber MH, Lippman SM, Waun Ki H (1994) Chemoprevention of head and neck cancer. Semin Oncol 21:366–375

    PubMed  CAS  Google Scholar 

  149. Lippman SM, Benner SE, Hong WK (1994) Cancer chemoprevention. J Clin Oncol 12:851–873

    PubMed  CAS  Google Scholar 

  150. Oridate N, Lotan D, Xu XC, Hong WK, Lotan R (1996) Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2:855–863

    PubMed  CAS  Google Scholar 

  151. Eicher S, Lotan R (1996) Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. Laryngoscope 106:1471–1475

    Article  PubMed  CAS  Google Scholar 

  152. Hong WK, Lippman SM, Itri LM, Karp DD, Lee IS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW, Goepfert H (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801

    Article  PubMed  CAS  Google Scholar 

  153. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK (1994) Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. I Natl Cancer Inst 86:140–141

    Article  CAS  Google Scholar 

  154. De Vries N, Pastorino U, Van Zandwijk N (1994) Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. Eur J Cancer Part B Oral Oncol 30:367–368

    Article  Google Scholar 

  155. Briggs RJ, Forastiere AA (1991) Isotretinoin for prevention of second primary squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 105:752–754

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Stupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. E. Vokes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stupp, R., Vokes, E.E. (1998). Kopf- und Halstumoren. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation